Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 26, 2026
IREN Limited (IREN) Shares Advance +11.5% in Past Month on AI Infrastructure Momentum

IREN Limited (IREN) Shares Advance +11.5% in Past Month on AI Infrastructure Momentum

Key Takeaways

  • IREN Limited shares rose roughly 11.5% over the last 30 days, from a close of $39.58 on August 26, 2026 to $44.13 on September 25, 2026.
  • The advance followed a post-earnings pullback in late August and a steady rebound in September driven by analyst upgrades and renewed AI-infrastructure momentum.
  • Fiscal 2026 results highlighted $4 billion in contracted annualized recurring revenue (ARR) and the delivery of the first Microsoft deployment, offsetting a large non-cash impairment.
  • Over the trailing three months, the stock remains down about 7.6%, reflecting a sharp July selloff tied to capital-spending concerns.
  • The shares still trade well below their 52-week high, leaving execution and funding of the company's expansion plan as key investor watch items.

IREN Limited (IREN) Business Model and Competitive Position

IREN Limited is a vertically integrated data-center and AI cloud-services company headquartered in Sydney, Australia. Founded in 2018 as Iris Energy, the company was renamed IREN Limited in November 2024 and has transitioned from renewable-powered Bitcoin mining toward high-performance computing and AI cloud infrastructure. IREN owns roughly 5 gigawatts of grid-connected power capacity across North America, Europe, and Australia, along with more than 150,000 GPUs installed or on order, giving it the power and compute footprint needed to serve hyperscalers and AI developers.

The company's strategy centers on owning the full infrastructure stack—land, power, data centers, compute equipment, and software—rather than acting only as a landlord or miner. This positioning, reinforced by contracts with major technology partners, is why investors follow IREN closely as a pure-play "neocloud" operator competing with peers such as Core Scientific (CORZ), Applied Digital (APLD), and TeraWulf (WULF). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

IREN Limited (IREN) Stock Price Performance Over 30 Days and the Quarter

IREN shares closed at $44.13 on September 25, 2026, up approximately 11.5% from the $39.58 close recorded 30 calendar days earlier on August 26. The move was not a straight line: the stock fell to about $35.45 on August 28 immediately after the company reported its fourth-quarter fiscal 2026 results, then recovered throughout September and reached an intra-month high near $48.55 on September 22 before easing into the end of the period.

The trailing three-month picture is more mixed. From a close of $47.74 on June 25, 2026, the stock declined about 7.6% to the latest level. The quarter included a sharp July drawdown that took shares to an intraday low near $28.93 on July 29, followed by a strong rebound. This pattern reflects a market that initially penalized IREN's heavy capital-expenditure and funding requirements, then rewarded improving execution and firmer AI-cloud demand.

Factors Behind the Recent 30-Day Advance

The most immediate catalyst was the company's fourth-quarter fiscal 2026 report, released in late August. IREN posted revenue of $137.2 million and a net loss of $684 million, driven largely by a $450.4 million non-cash impairment related to the decommissioning of Bitcoin mining hardware. The headline loss initially pressured the shares, but investors refocused on forward-looking metrics: $4 billion in contracted ARR for 2026 capacity, roughly $1 billion of operating ARR, and the delivery of Horizon 1, the first of four 50-megawatt liquid-cooled deployments for Microsoft (MSFT).

The subsequent September recovery was supported by a wave of analyst action. On September 14, JPMorgan issued a rare double-upgrade, lifting IREN to Overweight from Underweight and raising its price target to $65 from $46, citing customer-signing momentum, stronger neocloud pricing, and the company's relationship with Nvidia (NVDA). Northland Capital followed on September 18 with an Outperform rating and a $99 target, while B. Riley reiterated a Buy rating with a $96 target. These calls emphasized rising contract pricing—three-year rates up roughly 125% and five-year rates up about 70%—and IREN's growing traction in the AI-compute market.

Quarterly Performance Drivers and Execution Updates

The broader quarterly trend was defined by a conflict between rapid transformation and near-term uncertainty. During July, the stock sold off sharply as investors weighed the scale of IREN's build-out—management guided to $25 billion to $30 billion in fiscal 2027 capital expenditures—alongside declining Bitcoin mining revenue and concerns about financing. A pullback across AI-infrastructure names compounded the decline.

Sentiment then stabilized and improved as IREN demonstrated execution. The company closed its fiscal 2026 year with $4 billion of contracted ARR and a diversified customer base that includes Cohere, Prometheus, Perplexity, Figure AI, Fal AI, and Higgsfield AI. It also secured substantial GPU financing, including $3.6 billion at roughly 6% for its Microsoft contract and a separate $2.8 billion package. The partnership with Nvidia, including an Exemplar Cloud designation on GB300 NVL72 systems and an equity arrangement, further validated the company's infrastructure. These developments underpinned the recovery that lifted the stock off its July lows even as it remained below its 52-week high. I pulled up Tickeron’s AI Trend Prediction Engine to review the broader sector context around these moves.

Key Areas to Monitor Going Forward

Investors monitoring IREN should watch several factors in the months ahead. First is delivery execution, particularly the completion of Horizons 2 through 4 for Microsoft, which are targeted for the December quarter. Second is the pace of fiscal 2027 and 2028 contracting, where management has indicated late-stage discussions covering a significant portion of upcoming capacity. Third is the funding environment, given the scale of the planned capital-expenditure program and the company's reliance on GPU financing and customer prepayments. Finally, broader AI-infrastructure demand, GPU pricing, interconnection approvals in Texas, and the planned wind-down of Bitcoin mining by the end of 2026 will all influence sentiment. These are operational and market factors to monitor, not a basis for predicting future returns.

Using Tickeron Tools for Systematic Analysis

For traders and investors looking to apply a systematic approach to names like IREN, Tickeron's Trending AI Robots page offers a curated view of its AI-driven trading bots. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots differ in strategy, timeframe, and performance metrics, allowing users to compare approaches that suit different trading styles and risk profiles. The page is designed to help visitors quickly identify currently favored automated strategies, and those interested can explore the full selection to see how AI-powered signals might complement their own research. I find this resource helpful when cross-checking signals alongside fundamental developments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IREN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IREN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for IREN turned positive on September 04, 2026. Looking at past instances where IREN's MACD turned positive, the stock continued to rise in 44 of 48 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 04, 2026. You may want to consider a long position or call options on IREN as a result. In 65 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

IREN moved above its 50-day moving average on September 03, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IREN crossed bullishly above the 50-day moving average on September 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IREN advanced for three days, in 236 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where IREN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IREN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

IREN broke above its upper Bollinger Band on September 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. IREN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.155) is normal, around the industry mean (4.579). P/E Ratio (51.416) is within average values for comparable stocks, (30.282). IREN's Projected Growth (PEG Ratio) (3.106) is very high in comparison to the industry average of (0.811). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (19.048) is also within normal values, averaging (16.763).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IREN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 12.93B. The market cap for tickers in the group ranges from 590 to 308.32B. MS holds the highest valuation in this group at 308.32B. The lowest valued company is FSSLD at 590.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 16%. NCPL experienced the highest price growth at 84%, while AXG experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -49%. For the same stocks of the Industry, the average monthly volume growth was 30% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 74
Profit Risk Rating: 86
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
IREN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry InvestmentBanksBrokers

Industry
N/A
Address
55 Market Street
Phone
+61 279068301
Employees
685
Web
https://www.iren.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
IREN Limited (IREN) Shares Advance +11.5% in Past Month on AI Infrastructure Momentum